Background: For many patients with end-stage liver disease, liver transplantation represents the only curative therapy. Transplant recipients are scored and ranked using the model for end-stage liver disease (MELD/MELD-Na). Circulatory impairment is known to deteriorate outcomes; however, it is not incorporated into the current allocation system's score. The aim of our study is to analyze the predictive value of copeptin as a biomarker of circulatory impairment and increased short-term mortality risk in patients with end-stage liver disease. Methods: We conducted a retrospective observational study of 615 patients with end-stage liver disease. Patients were recruited using assessments performed during the evaluation process for liver transplantation. Copeptin values were analyzed in comparison to MELD-Na, interleukin 6 (IL-6), and C-reactive protein (CRP). Results: Elevated levels of copeptin, IL-6 and CRP, as well as high MELD-Na scores, were significantly correlated with mortality. In a comparison of copeptin-tertiles, patients in group T3 (16.3 pmol/L or more) showed a significantly higher mortality risk (hazard ratio 11.2, p < 0.001). After adjusting for MELD-Na, copeptin remains an independent predictor of mortality. It shows its greatest prognostic strength in short-term mortality, where it performs comparable to MELD-Na (AUROC for 7 day-mortality, 0.941/0.939; p = 0.981) and shows an additional predictive value to MELD-Na for short-term mortality (7 days, p: 0.046; 30 days, p: 0.006). Conclusions: Copeptin presents a valuable individual biomarker in detecting patients at risk for short-term mortality. Further studies should be performed to confirm our findings.
Introduction
Liver cirrhosis, a consequence of the fibrotic reorganization of liver tissue, marks the endpoint of chronic liver disease. This process leads to the impairment of organ function, and finally, organ failure. To date, liver transplantation represents the only available curative therapy option for patients with end-stage liver disease. For these patients, a valid mortality prediction is needed that can be used to stratify eligible transplant recipients.
In most countries, patients are ranked according to disease severity as determined by the model of endstage liver disease (MELD) [1, 2] . The MELD score, which is based on bilirubin and creatine levels, as well as the international normalized ratio (INR), is an objective mathematical model used to estimate patients' 3-month mortality risk. The MELD scoring system has been further developed by incorporating sodium into the score (MELD-Na score) [3] .
Complications of end-stage liver disease, such as visceral bleeding, hepatic encephalopathy, acute-onchronic liver failure and inflammation, are known to have a significant influence on patient mortality [4] [5] [6] [7] . However, bilirubin, INR, creatinin and sodium only have a limited informative value regarding these complications. Consequently, in several situations, the MELD score has significant limitations for predicting mortality risk [8] .
Copeptin, a 39 amino-acid peptide, is already considered to have prognostic strength in patients with sepsis or septic shock [9] [10] [11] . Furthermore, copeptin is diagnostically conclusive in myocardial infarction, acute heart failure and trauma [12] [13] [14] . Copeptin is released in neurohypophysis along with a signal-peptide, arginine vasopressin (AVP), and neurophysin II. Although the physiological function of copeptin is mostly unknown, its equimolar release makes copeptin an ideal surrogateparameter of the difficult-to-measure AVP, which only has a half-life of about 12-24 min [15] [16] [17] . Vasopressin, as a part of the osmoregulatory system, has two functions: it increases systemic vascular resistance, and it increases water reabsorption in the kidneys.
As a consequence of the systemic circulatory dysregulation in cirrhotic patients characterized by a volume shift between central hypovolemia and peripheral hypervolemia, AVP is upregulated to compensate for this state [18] . The systemic inflammatory response syndrome (SIRS) and sepsis, which have similar effects on circulation [19] , can deteriorate the existing circulatory impairment and worsen patients' prognosis. Hence, early diagnosis could improve outcomes.
The aim of our study is to analyze the predictive value of copeptin in comparison to MELD and MELD-Na scores as they relate to liver and renal function, serum electrolytes, and inflammation.
Materials and methods

Study population and materials
We conducted a retrospective observational study on a cohort of 615 patients, who were recruited from patients undergoing the evaluation process for liver transplantation at the University Hospital of Leipzig. The Ethics Committee at the Leipzig University Faculty of Medicine approved the retrospective usage of residual material and data for our study (Nr. 039-14-27012014). Sera of patients were stored at −80 °C for the measurement of additional parameters not routinely included in the evaluation process. Clinical chemistry was performed at the Institute of Laboratory Medicine, University Hospital of Leipzig. Serum copeptin levels were analyzed by using immunologic trace (time-resolved amplified cryptate emission) technology on the automatized KRYPTOR compact PLUS analyzer (Thermofisher/ Brahms, Waltham, MA, USA). Sample volumes required for measurement were 50 μL. According to the manufacturers specifications, limit of blank (LOB) and limit of detection (LOD) were 0.41 pmol/L and 0.69 pmol/L, respectively. The direct compound range was between 0.7 pmol/L and 500 pmol/L and up to 2000 pmol/L after dilution. The intra-assay coefficient of variation (CV) were 15.0% or less (2.0 pmol/L-4.0 pmol/L: <15.0%; 4.0 pmol/-15 pmol/L: <8.0%; 15.0 pmol/L-50 pmol/L: <4.0%; >50 pmol/L: <3.0%; >500 pmol/L: <4.0%), the inter-assay COV 18.0% or less (2.0 pmol/L-4.0 pmol/L: <18.0%; 4.0 pmol/-15 pmol/L: <10.0%; 15.0 pmol/L-50 pmol/L: <5.0%; >50 pmol/L: <5.0%; >500 pmol/L: <6.0%). Serum interleukin 6(IL-6) levels were measured by using the automatized immunological assay on Cobas e 801 (Roche Diagnostics, Mannheim, Germany). The limit of blank (LOB) and limit of detection (LOD) were 1.0 pg/mL and 1.5 pg/mL, respectively. According to the manufacturer's specifications, the measuring range was between 1.5 pg/mL and 5000 pg/ mL. Regarding repeatability, the CV of repetition accuracy was below 14.4%.
Bilirubin, creatinine and C-reactive protein (CRP) were analyzed according to the manufacturer's specifications on a COBAS C-system 8000 and an E-modul (Roche Diagnostics, Mannheim, Germany). The INR was ascertained via an ACL TOP 700 System (Instrumentation Laboratory, Lexington, MA, USA). Copeptin, MELD, MELD-Na, IL-6 and CRP were available in 609, 613, 609, 554 and 594 cases, respectively. Because of the small number of missing parameters, complete-case analyses were performed instead of using imputation methods. Clinical data was obtained from patient records.
MELD and MELD-Na scores were calculated based on the guidelines of UNOS (United Network of Organ Sharing) using the following formulas: MELD score = 10 × {0.957 × Ln (creatinine [mg/ dL]) + 0.378 × Ln (bilirubin [mg/dL]) + 1.120 × Ln (INR) + 0.643}. Creatinine, bilirubin and INR values lower than 1.0 were set to 1.0. The maximum value of creatinine was 4.0. If patients underwent dialysis, creatinine was also set to 4.0.
MELD-Na score = MELD + 1.32 × (137 - Na) - [0.033 × MELD × (137 - Na). Serum sodium values lower than 125 mmol/L were set to 125 mmol/L, and values higher than 137 mmol/L were set to 137 mmol/L [20] .
Statistics
Statistical analyses were performed with SPSS version 24.0 (SPSS Inc., Chicago, IL, USA), Microsoft Excel (Microsoft, USA), and R (R Foundation for Statistical Computing, Vienna, Austria) software.
To compare the results of different groups of patients, medians and interquartile ranges (IQRs) were used. Mann-Whitney U and Pearson's χ 2 -tests were used to investigate whether the two groups were significantly different. Correlation analyses were performed using Spearman's correlation.
For survival analyses, patients were divided into tertiles according to their baseline values of copeptin, MELD, MELD-Na, IL-6 and CRP. The MELD score was not limited at 40 for comparison analyses. Kaplan-Meier analysis, the log-rank test and Cox proportional hazards regression model was calculated to compare the different subgroups. Patients who underwent liver transplantation were censored at the date of transplantation for Kaplan-Meier analysis and Cox regression.
Receiver operating characteristics (ROC) and area under ROC (AUROC) were used to depict the predictive value of copeptin, MELD/MELD-Na, and CRP at different points in time, namely 7 days, 30 days, 90 days and 365 days. The DeLong test was used to compare AUROCs.
Results
Baseline characteristics
The baseline characteristics of our cohort are shown in Table 1 . A total of 615 patients undergoing evaluation for liver transplantation were enrolled in this study, and 381 (62.0%) of them were men. The median age of the whole cohort was 57.2 (IQR: 50.6-63.1). The median followup time was 282 days (IQR: 41.5-586.0). Five hundred and sixty-four (91.7%) patients suffered from definite cirrhosis, five (0.8%) patients who has sustained acute liver failure, the remaining 46 (7.5%) patients presented with chronic liver insufficiency. Within the follow-up time, 100 patients who did not receive liver transplantation died (17.8%), and 54 underwent liver transplantation (8.8%).
Most of the end-stage liver disease in the cohort was caused by alcohol abuse (63.4%), followed by cryptogenic cirrhosis (10.2%) and viral hepatitis (8.5%). The median copeptin level was 9.3 pmol/L (IQR: 4.6-22.5, range: 0.7-674.1), while the median MELD was 11.0 (IQR: 8.5-16.7, range: 6.4-40.0), and the median MELD-Na was 11.7 (IQR: 8.6-19.2, range: 6.4-40.0).
A review of patient records revealed visceral bleeding in 142 patients (23.1%), hepatocellular carcinoma (HCC) in 99 patients (16.1%), and spontaneous bacterial peritonitis (SBP) in 81 patients (13.2%). These complications could have occurred at any point throughout the entire followup period.
Correlation and survival analysis
When deceased and surviving patients were compared, there were no significant differences in age and sex. Deceased patients showed significantly higher copeptin (median: 36.8 pmol/L vs. 7.5 pmol/L), MELD/MELD-Na, bilirubin, creatinine, INR, IL-6, and CRP results (Supplementary Material, Table 1 ). The relationship between copeptin concentrations, MELD scores, and the mortality of individual patients is illustrated in Supplementary Material, Figure 1 . Copeptin shows a strong correlation with MELD/ MELD-Na (0.581/0.579, p < 0.001) and its components bilirubin (0.406, p < 0.001), creatinine (0.565, p < 0.001), and INR (0.407, p < 0.001), as well as IL-6 (0.573, p < 0.001), CRP (0.469, p < 0.001), and cystatin C (0.653, p < 0.001). Negative correlations were observed for sodium (−0.250, p < 0.001), hemoglobin (−0.475, p < 0.001), and platelet count (−0.111, p = 0.007).
For the survival analysis, we divided patients into three groups according to tertiles of baseline copeptin, MELD/MELD-Na, IL-6, and CRP values. Figure 1 shows the Kaplan-Meier curve of copeptin at 365 days of follow-up (detailed mortality data is shown in Table 2 ). Copeptin, as well as MELD/MELD-Na, IL-6 and CRP, were strongly associated with mortality. Elevated copeptin levels were strongly related to increased mortality risk over various time intervals (7, 30, 90 and 365 days). Cox regression analyses were performed to analyze the predictive value of copeptin in mortality prediction. The analyses show differences between group T1 and groups T2 and T3: mortality risks in groups T2 and T3 are significantly higher than in T1 (hazard ratios, 2.3 [p = 0.035]; 11.2 [p < 0.001]). After adjusting for MELD/ MELD-Na, elevated copeptin levels >16.3 pmol/L were shown to be independent predictors of mortality (Table 3) . A Cox regression was also calculated for continuous variables. A 1 pmol/L increase of copeptin is associated with a hazard ratio of 1.009 (p < 0.001). This effect remains significant after adjusting for MELD-Na (hazard ratio 1.004, p < 0.001). A one pmol/L increase of copeptin is also Numbers in parentheses are adjusted for MELD, numbers in parentheses and italics are adjusted for MELD-Na. T1 was used as reference category. Patients were censored at the day of transplantation or end of follow-up.
independently associated with 7-day mortality (odds ratio 1.006 [p = 0.046]) and 30-day mortality (odds ratio 1.013 [p = 0.006], logistic regression adjusted for MELD-Na).
To compare the biomarkers' predictive power for different time periods (7, 30, 90 and 365 days), we performed a receiver operating characteristics (ROC) analysis of copeptin, MELD scores, IL-6 and CRP. Curves and corresponding areas under the ROC (AUROC) are shown in Figure 2 . Copeptin shows prognostic strength for shortterm mortality. When predicting 7 day-mortality, the single parameter copeptin (AUROC, 0.941) performed as well as the MELD/MELD-Na score, which is assembled out of three or four single parameters (AUROC, 0.941/0.939, p = 0.791/0.981). Copeptin also performed better than IL-6 and CRP (AUROC, 0.923/0.789, p = 0.125/ < 0.001). For a closer examination of the patients with 7-day mortality, we compared these patients' biomarker levels with the remainder of the cohort (Table 4 ).
Discussion
In our study, copeptin was a valid parameter for mortality prediction in patients with end-stage liver disease, especially for short-term mortality. For the first time, we show that copeptin and MELD scores could help identify patients' 7-day mortality risk. The underlying pathophysiological mechanism causing the copeptin elevation should be elucidated in further studies. In the literature, elevated copeptin has been associated with portal hypertension, a state leading to increased resistance in intrahepatic liver vessels [21] . This increase in portal pressure causes various changes in the cirrhotic patients' systemic circulation. In this study, low platelets, which are known to be related to portal hypertension levels, were associated with higher copeptin levels. As a consequence of portal hypertension, vasodilatation in the splanchnic circulation leads to reduced central perfusion and systemic hypotension with a shift in volume distribution, which causes central hypovolemia and peripheral hypervolemia [18, 22] . Consequently, vasodilatation in the mesenteric circulation causes hypoperfusion in several organ systems, including the kidneys. Due to this mismatch in organ perfusion, the organism reacts by upregulating the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS), as well as releasing vasopressin, which causes water and sodium retention [18, 23] . All these different processes lead to a 'hyperdynamic state', which is characterized by increased cardiac output and heart rate in addition to decreased vascular resistance and low blood pressure [24] . This problem is further aggravated by the use of diuretics in these patients. Consequently, an elevated release of AVP, and, respectively, copeptin, is a compensatory mechanism to regain sufficient organ perfusion.
Another possible explanation for the loss of systemic resistance and hypotension could be systemic inflammation. As mentioned, inflammation represents a major determinant of mortality in cirrhosis. Systemic inflammation is responsible for many complications worsening the outcomes of patients with end-stage liver disease and has been linked to variceal bleeding, hepatic encephalopathy and acute-on-chronic liver failure [4] [5] [6] [7] . Established liver scoring systems like the Child-Turcotte-Pugh score or MELD do not consider any parameters related to the organism's inflammatory response. Different studies could achieve an increased predictive value by adding parameters of inflammation, such as adding CRP to the MELD score [25, 26] . We recently introduced IL-6 as a valid parameter of mortality prediction in patients with end-stage liver disease [27] . Remarkably, in this study, copeptin showed a strong correlation with the inflammation parameters IL-6 and CRP. This could be a hint that copeptin elevation could also be a consequence of systemic inflammation in these patients as other studies with different cohorts of patients have already established a connection between elevated copeptin levels and the incidence of SIRS or sepsis [10, 11] . Due to the large number of patients suffering from HCC (n = 99), we also performed survival analysis by censoring these patients to avoid impact on our findings. After exclusion of there were no significant differences in our results.
In contrast to other studies on end-stage liver disease that introduced copeptin as a prognostic factor in long and mid-term survival [28] [29] [30] , we observed the prognostic value is especially strong in short-term survival, namely within 7 days. Interestingly, in comparison to MELD and MELD-Na scores, which are composed of three or four parameters, copeptin, as a single parameter, achieves equal results in mortality prediction.
Our study has some limitations. First, it was designed as a monocentric retrospective observational trial, so we were unable to investigate the pathogenetic mechanism of the strong association between copeptin and shortterm mortality. Second, although our cohort represents a typical consistency regarding the etiologies of end-stage liver disease, the most common cause of cirrhosis was alcohol-induced. Due to these factors and the limited number of patients, a subgroup analysis was barely Table 4 : Comparison of deceased and surviving patients (7-day mortality).
7-Day mortality (n = 38)
All patients, excluding 7-day mortality (n = 523) p-Value practicable. Third, vital parameters namely heart rate and blood or information about ascites were not available. Hence, an additional analysis was not possible.
In summary, in this study, we showed the prognostic strength of copeptin in comparison and in addition to the MELD score. Within a period of 7 days, the single parameter copeptin achieves equal results in mortality prediction compared to MELD diagnostics. Hence, copeptin represents a sensitive biomarker in clinical usage that can detect critical patients independent of transplantation. Further studies should be performed to confirm our findings.
